Podcasts about Personalized medicine

America Out Loud PULSE with Dr. Myriah Hinchey – Childhood vaccines spark intense debate in modern healthcare. Dr. James Neuenschwander explores vaccine history, ingredients, immune vulnerability, and rising chronic illness in children. This conversation examines individualized risk, parental autonomy, informed consent, and the urgent need for transparent safety data and personalized approaches to pediatric health...

In this Your Health University episode, Jamie sits down with Nurse Practitioner, Brooke Howard, President of Clinical Operations, to talk about Biote, wellness, and bioidentical hormone optimization—and why it has been life-changing for both of them. Brooke shares how a trusted colleague pushed her to look deeper when she was exhausted, gaining weight, and “holding it together by a thread.” Jamie opens up about anxiety, ADD medication, and how feeling hormonally balanced gave him the confidence to step into a new chapter. This conversation is for anyone who feels “off,” has been told their labs are “normal,” and wants to explore a more complete picture of wellness. www.YourHealth.Org

America Out Loud PULSE with Dr. Myriah Hinchey – Childhood vaccines spark intense debate in modern healthcare. Dr. James Neuenschwander explores vaccine history, ingredients, immune vulnerability, and rising chronic illness in children. This conversation examines individualized risk, parental autonomy, informed consent, and the urgent need for transparent safety data and personalized approaches to pediatric health...

Reflections on the Peter Attia/Epstein scandal; How to lower lp(a)—does diet help? What are bio-active peptides? Could they stave off kidney disease? Scientists just tested the fittest 81-year-old in the world—here's what they found; Media erroneously report that intermittent fasting is not effective for weight loss; Sugary drinks may stoke anxiety in teens; Omega-3s support kids' reading fluency and spelling scores; Surprising study shows saturated fats not harmful to kidneys.

Dr. Marbas outlines essential lab tests and special panels for vegans, including CBC, B12, vitamin D, omega-3s, iron, and inflammation markers. #VeganHealth #PreventiveLabs #NutritionTracking #WellnessCheck

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden speaks with Dr. Anthony Beck about the evolving landscape of functional medicine and the importance of personalized health approaches. They discuss the challenges patients face in navigating conflicting health information, the significance of integrating multiple health assessments, and the role of genetics in understanding individual health. Dr. Beck emphasizes the need for collaboration among healthcare providers and the empowerment of patients in their health journeys, advocating for a comprehensive and individualized approach to wellness.    For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways ·       Dr. Beck emphasizes the importance of a comprehensive approach to health. ·       Personal experiences often shape a practitioner's journey in medicine. ·       Functional medicine is evolving and adapting to new challenges. ·       Patients often face conflicting information in the health space. ·       Understanding personal health data is crucial for effective treatment. ·       Integrating multiple health assessments provides a clearer picture. ·       Genetics play a role, but they don't dictate health outcomes. ·       Social media can complicate health information and trends. ·       Collaboration among healthcare providers enhances patient care. ·       Empowering patients to take charge of their health is essential.   Chapters 00:00 Introduction to Longevity and Education 03:38 Personal Journey and Background of Dr. Beck 07:49 Transitioning to Functional Medicine 10:54 Navigating the Information Overload 14:35 The Importance of Individualized Medicine 18:22 Creating a Comprehensive Testing Framework 21:10 Understanding Genetic Testing and Personalized Medicine 24:14 The Importance of Foundational Health Data 27:10 Navigating the Longevity Space: Myths and Realities 31:19 The Complexity of Health: Beyond Simple Solutions 33:54 The Role of Collaboration in Patient Care 37:51 Empowering Patients: Taking Control of Health Decisions   To learn more about Dr. Anthony Beck: Email:  dragb@dranthonygbeck.com Website: balanceprotocol.com Instagram: @balanceprotocol Facebook: @balanceprotocol   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

Send us a textIs there a better way to heal—one that doesn't rely on endless prescriptions?In this episode of Unlimited with Elisabeth Carson, Elisabeth Carson sits down with Sam Tejada, a former firefighter turned leader in biohacking, longevity, and personalized medicine.Sam shares how years on the front lines of emergency medicine exposed the flaws in the traditional healthcare system—and what he discovered when he shifted into preventative and functional medicine. This conversation explores how data-driven diagnostics, lifestyle changes, and individualized health strategies can completely change the way we heal.If you're interested in biohacking, longevity, functional medicine, or taking a proactive approach to your health, this episode breaks it down in a clear, grounded way—without hype or extremes.✨ Follow Me or Join the Journey:Your first step towards peace: https://unlimitedmeditationpack.com/Text UNLIMITED to (954) 539-1259 for updates on when Elisabeth goes live, drops a new podcast, or exclusive updates on what's happening with her community

In this episode of The Better Life, Dr. Pinkston welcomes back her favorite compounding pharmacist, Ray Solano of PD Labs. Together, they pull back the curtain on the skincare industry, revealing why a high price tag doesn't always equal high quality. Ray introduces his new Skin Lasting line—pharmacist-designed formulations that prioritize stable, bioavailable ingredients like Vitamin C, glutathione palmitate, and GHK copper peptides over fancy packaging. The conversation also tackles the "Super Bowl of Sugar" and its impact on internal health, which invariably reflects on the skin. Beyond aesthetics, Dr. Pinkston and Ray discuss the critical role of compounding pharmacies in making healthcare affordable and customized. From natural thyroid solutions to tailored GLP-1 weight loss dosages, learn how personalized medicine can save you money and reduce side effects by giving you exactly what your body needs. Key Takeaways from the Show Inside-Out Health: Your skin is a window into your gut health; issues like eczema or psoriasis are often internal signals. The "Skin Lasting" Line: Ray explains the science behind his new serums, including the C+ Serum for daily defense and Lift Up for collagen production. The Compounding Advantage: Why "one size fits all" dosages in pharmaceutical medicine often fail patients and how customization can improve outcomes. Affordability: Discover how compounding pharmacies can offer significant savings on medications like natural thyroid and peptides. Special Offer: Listeners can get $25 off their prescription at PD Labs by mentioning Better Life TV or Dr. Pinkston. See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and trends shaping the industry landscape, offering insights into how companies are navigating scientific, regulatory, and market challenges.The pharmaceutical and biotech sectors are in a dynamic period marked by substantial scientific advancements and strategic developments. Among the key players, Sanofi is demonstrating resilience despite geopolitical challenges affecting vaccine policies in the United States. The company's CEO, Paul Hudson, remains optimistic about their vaccine portfolio even amidst a slight downturn in vaccine sales, which decreased by 2.5% in the fourth quarter of 2025 and 1.2% for the entire year. This scenario highlights the broader industry challenge of maintaining focus on long-term goals while adapting to fluctuating market dynamics. In parallel developments, Sanofi has decided to discontinue its efforts to develop a next-generation mRNA seasonal flu vaccine after two and a half years of attempting to revolutionize flu prevention with mRNA technology. This halt underscores the challenges associated with mRNA vaccines in addressing seasonal flu strains despite their success during the COVID-19 pandemic.Roche is gearing up for an eventful 2026 with ten new molecules entering late-stage testing. Potential launches, including the breast cancer candidate giredestrant, are on the horizon. However, they face challenges as their eye drug Vabysmo underperformed against projections, and their Tecentriq failed in an early lung cancer study. These outcomes underscore the inherent risks of pharmaceutical research and development, illustrating how clinical trial results can substantially impact company trajectories. Additionally, Roche has decided to remove Kiniksa's fibrosis drug from its Phase 2 pipeline as part of a broader quarterly review. This decision reflects ongoing reassessment activities by pharmaceutical companies aiming to optimize resource allocation and focus on promising candidates. Roche also unveils its ambition to become a major player within obesity treatment markets—directly challenging industry leaders like Novo Nordisk—by securing top-three positioning during company earnings presentations last year—a strategic pivot towards obesity reflecting broader industry trends focusing increasingly upon metabolic disorders amid rising global prevalences thereof worldwide today.In a notable achievement, Tenpoint Therapeutics has secured FDA approval for Yuvezzi, an innovative vision-correction eye drop addressing presbyopia—a common age-related condition. The approval stems from combining two existing eye drop formulations, showcasing how repurposing compounds can lead to new therapeutic options. With $235 million raised to support its Q2 launch, Tenpoint's confidence in Yuvezzi's market potential is clear.The biopharma merger and acquisition landscape is evolving as companies shift focus from acquiring blockbuster drugs to enhancing capabilities across the drug development continuum. This strategic pivot reflects a more integrated approach to growth, aimed at building comprehensive portfolios that address various stages of drug commercialization and development.AstraZeneca has announced a substantial $15 billion investment in China by 2030 to expand its cell therapy and radioconjugate capabilities. This move underscores China's strategic importance as a biopharma market and highlights AstraZeneca's commitment to leveraging innovative technologies to enhance therapeutic offerings. AstraZeneca is making significant strides with this investment aimed at advancing its capabilities in China through 2030. This strategic move highlights the growing importance of personalized medicine and targeted therapies in emerging markets like China.ReguSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a whirlwind of activity in the industry, where scientific breakthroughs, regulatory shifts, and strategic collaborations are all reshaping the future of healthcare.Let's start with a look at the ongoing efforts by the Trump administration to negotiate Medicare drug prices under the Inflation Reduction Act. This initiative is set to impact 15 high-profile drugs, marking a significant push towards more stringent pricing regulations. The aim is to make medications more affordable for patients, but this move could also compel pharmaceutical companies to rethink their pricing strategies and revenue models. Such regulatory changes underscore a broader trend toward cost containment in healthcare, a critical issue as drug prices continue to be a major concern for policymakers and consumers alike. Additionally, proposed changes to Medicare Advantage rates by the Trump administration could lead to benefit cuts or market exits by insurers, highlighting ongoing uncertainties in healthcare financing that could significantly impact patient access to care.In the realm of oncology, Johnson & Johnson has achieved another milestone with its Darzalex Faspro. This drug has received FDA approval for an expanded indication in treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplants. This approval is not just a regulatory win; it reflects the growing importance of combination therapies in enhancing treatment outcomes for complex diseases like multiple myeloma. The shift towards combination regimens is a notable trend in oncology, aiming to maximize therapeutic efficacy and improve patient survival rates.Meanwhile, Teva Pharmaceuticals is bracing for a potential slowdown come 2026 after a period of growth. This projection highlights the inherent volatility in the pharmaceutical market, where external factors such as regulatory changes and competitive pressures can swiftly alter financial trajectories. Companies like Teva must remain agile and adaptable to navigate these unpredictable waters.On the innovation front, Cellares has secured $257 million in a Series D funding round aimed at expanding its cell therapy contract manufacturing operations globally. This significant investment underscores an increasing demand for advanced therapeutic manufacturing capabilities, reflecting the industry's pivot towards personalized medicine and cell-based therapies. As the landscape of medicine shifts towards more individualized approaches, companies like Cellares are positioning themselves at the forefront of this transformative trend.Novo Nordisk is actively exploring new growth avenues, with its business development head engaging in numerous strategic meetings at the J.P. Morgan Healthcare Conference. This proactive approach illustrates how critical partnerships and acquisitions are becoming for pharmaceutical companies looking to maintain a competitive edge and drive innovation forward. Novo Nordisk's pursuit of Metsera aligns with broader industry trends where strategic acquisitions are leveraged to bolster pipelines with innovative therapies.Pfizer continues to dominate the vaccine production arena despite challenging market conditions that have seen competitors like Sanofi face setbacks. This leadership can be attributed to Pfizer's robust product pipeline and strong relationships with healthcare providers, highlighting how trust and reliability remain crucial components of success in this field.In gene therapy news, Eli Lilly has forged a $1.1 billion agreement with Seamless Therapeutics aimed at developing gene-editing medications for hearing loss. This collaboration is indicative of gene therapy's expanding scope, offering hope for addressing previously untreatable conditions Support the show

Whether you're curious about the emotional side of healthcare, searching for ways to take more ownership of your wellbeing, or interested in holistic approaches to longevity and healing, this episode is packed with wisdom, actionable insights, and heartfelt stories.Eric Pennington is joined by Dr. Mark Sherwood for an eye-opening conversation about the crossroads of healthcare, emotional intelligence, and the choices we make around our well-being.In this episode, Eric and Dr. Sherwood dig deep into the emotional impact of health challenges, the staggering rise in lifestyle-related diseases, and how our everyday decisions—from what we eat to how we respond to stress—shape both our physical and emotional health. Dr. Sherwood shares fascinating perspectives on the Standard American Diet, the addictive nature of certain foods, and the importance of trust and empathy between doctor and patient.You'll also learn how Dr. Sherwood and his wife, Dr. Michelle Sherwood, have built an alternative medical practice centered on treating the whole person—spiritually, emotionally, mentally, and physically. Mark offers practical advice for managing healthcare costs, becoming more intentional about your health, and fostering hope and compassion in medical interactions.Moments00:00 America's Health Crisis Worsens05:11 "Processed Foods as Addictive Drugs"07:34 "Relearning Lifestyle Beyond GLP1"09:50 Focusing on Positivity First14:44 Specialist's Approach to Personalized Care18:46 "Creating Alternative Healthcare Systems"20:51 "Rethinking Health Savings Systems"25:17 Webinar for Transparency and Engagement28:40 Holistic Health and Spiritual Connection32:05 Freedom to Choose Beliefs33:50 "Power of the Professional Pause"37:26 "Patient Recognition and Connection"40:46 "Lost Personal Connection Today"44:08 Personalized Medicine for Diabetes48:14 Women's Health Dismissal Struggles52:29 "Longevity and Health Optimization"56:10 "Mark's Inspiring Message Shared"Here are 3 thought-provoking takeaways:Healthcare Is More Than Just Medication and Diagnosis - Dr. Sherwood advocates for a partnership with patients, focusing on trust, empathy, and really listening to their stories. Creating genuine relationships leads to better health outcomes—and patients know when you truly care.Lifestyle Choices Account for the Majority of Our Health - The conversation highlights that up to 90% of recurring health conditions are tied to lifestyle, not just genetics or bad luck. Nutrition, sleep, movement, and stress management are critical pillars—and we have more control than we think.Treat the Whole Person, Not Just the Symptoms - Mark and Michelle Sherwood's practice looks at physical, emotional, spiritual, and intellectual health—helping people feel seen, heard, and valued. It's a reminder that no one is defined by a diagnosis; we are all more than our medical charts.Mark Sherwood, Naturopathic Doctor (ND) and Michele L. Neil-Sherwood, Doctor of Osteopathy (DO), have a full-time wellness-based medical practice in Tulsa, OK called the Functional Medical Institute where they adopt a whole person approach, which is outcome based looking at each individual's unique needs. Their goal is to lead people down a pathway of true healing. To that end, there are two purposes: 1. To eradicate all self-imposed, choice driven disease conditions, and 2. To eliminate the usage of unnecessary medications. Through their unique clinic, various diagnostic tests are used, healing and prevention of common disease patterns are the norm. The couple has co-authored four Amazon #1...

Dr. Eric Gordon—Medical Director at Gordon Medical Associates and President of the Gordon Medical Research Center—joins Dr. Karlfeldt for a wide-ranging conversation on what it really takes to help “end-of-the-line” patients with complex, chronic illness. With 45+ years of clinical experience and deep involvement in research on ME/CFS, Lyme disease, and autoimmune conditions, Dr. Gordon offers a grounded, clinician-to-clinician look at why so many patients remain undiagnosed, misunderstood, or stuck despite seeing multiple providers.In this episode, you'll learn why chronic illness is rarely “in the book,” and why recovery often requires detective work across toxin load, infectious burden, genetics, immune dysfunction, and environmental triggers. Dr. Gordon breaks down how modern medicine's siloed specialties can miss multi-system patterns—and why tools like advanced testing and AI may become essential to sift exploding research (like microbiome discoveries) into something clinically useful. They also explore the evolving landscape of long COVID research, the importance of identifying patient subtypes (instead of lumping everyone into one diagnosis), and what this shift could mean for faster, more affordable healing.If you've tried the “usual” protocols and still don't improve, this conversation reframes the journey: why complexity doesn't mean hopelessness—and how the next wave of systems biology, smarter data-mining, and targeted interventions may finally change the game for chronic fatigue, Lyme, mold illness, and beyond.Key Topics CoveredWhy “complex chronic illness” usually isn't a simple diagnosis—and why that matters for treatmentThe “end-of-the-line” patient: what it means when you've already seen many good doctorsHow toxin load, infections, genetics, and terrain combine into a personalized illness patternWhy medical silos and protocol-based care often fail complex patientsMold exposure and mycotoxin sensitivity: why environment can block progressMast cell activation and reactivity: why treatment tolerance can be a major barrierThe microbiome information explosion—and why AI is becoming necessary to interpret itGarbage-in/garbage-out in AI: why context and quality data still matterLong COVID as a turning point: validating post-viral illness and advancing immune researchThe importance of subtyping ME/CFS, long COVID, and Lyme presentations to find what actually works _______________________________The Karlfeldt Center offers the most cutting-edge and comprehensive Lyme therapies. To schedule a Free 15-Minute Discovery Call with a Lyme Literate Naturopathic Doctor at The Karlfeldt Center, call 208-338-8902 or email info@TheKarlfeldtCenter.comCheck out Dr. K's Ebook: Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery here: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lymeUse the code LYMEPODCAST for a 100% off discount!

The Future of Longevity, Conscious Aging & Medical-Grade Health Optimization In this episode, we dive deep into the evolving world of longevity medicine, proactive health management, and conscious aging. Our conversation explores how modern medicine is shifting away from sickness management and toward preventive, personalized, and data-driven health optimization. We discuss topics like: Why aging should be treated as a renewable system The difference between health management vs. sickness management Hormonal pauses, menopause, and andropause Medical-grade IV "oil changes" and nutrient optimization Peptides, stem cells, exosomes, and regenerative therapies The future role of AI in personalized medicine Why intuition, lifestyle, and self-awareness matter more as we age This episode challenges conventional healthcare thinking and offers a forward-looking perspective on how humans can extend healthspan to match lifespan, while maintaining clarity, energy, and purpose.

In this episode of the BiohackingVille podcast, host Rob Rene sits down with Scott Nelson at the TAM Center in Tijuana, Mexico. They discuss alternative treatments for cancer and autoimmune diseases that exist outside the traditional medical system. Scott explains how the center was established to offer cutting-edge, customized treatments that aren't available in the United States due to regulatory and financial restrictions. They delve into the importance of personalized medicine, the role of nutrition and exercise in treatment, and the benefits of integrated medical and scientific collaboration at the center. The episode also highlights the challenges of the US medical system and the innovative strides being made in Mexico..00:00 Introduction to BiohackingVille00:47 Welcome to the TAM Center01:23 Scott Nelson's Journey to Tijuana01:48 Reopening the Hospital and Early Successes02:19 Innovative Cancer Treatments and Misdiagnosis04:31 Challenges and Advantages of Operating in Mexico08:00 Personalized Medicine and the Role of CPI08:42 The Importance of Comprehensive Testing14:14 Integrating Science and Medicine on the Sixth Floor15:41 Conclusion and Final Thoughts

As 2026 gets underway we know that many take time around this new beginning to improve not only their physical, but also their mental health. With that in mind, we're rerunning an episode with Leanne Williams on the future of depression care. Leanne is an expert on clinical depression and is working on new ways to more precisely diagnose depression in order to develop more effective treatment. For anyone who has suffered from depression or knows someone who has, it's an episode that provides hope for what's on the horizon. We hope you'll take another listen and also share this episode with anyone who you think may benefit from the conversation. Episode Reference Links:Stanford Profile: Leanne WilliamsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Leanne Williams, a professor of Psychiatry and Behavioral Science at Stanford University.(00:01:43) What Is Depression?Distinguishing clinical depression from everyday sadness.(00:03:31) Current Depression Treatment ChallengesThe trial-and-error of traditional depression treatments and their timelines.(00:06:16) Brain Mapping and Circuit DysfunctionsAdvanced imaging techniques and their role in understanding depression.(00:09:03) Diagnosing with Brain ImagingHow brain imaging can complement traditional diagnostic methods in psychiatry.(00:10:22) Depression BiotypesIdentifying six distinct biotypes of depression through brain imaging.(00:12:31) Cognitive Features of DepressionHow cognitive impairment plays a major role in certain depression biotypes.(00:14:11) Matching Treatments to BiotypesFinding appropriate treatments sooner using brain-based diagnostics.(00:15:38) Expanding Treatment OptionsPersonalizing therapies and improving treatment outcomes based on biotypes.(00:19:03) AI in Depression TreatmentUsing AI to refine biotypes and predict treatment outcomes with greater accuracy.(00:22:15) Psychedelics in Depression TreatmentThe potential for psychedelic drugs to target specific biotypes of depression.(00:23:46) Expanding the Biotypes FrameworkIntegrating multimodal approaches into the biotype framework.(00:27:29) Reducing Stigma in DepressionHow showing patients their brain imaging results reduces self-blame and stigma.(00:29:38) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of remarkable advancements and strategic collaborations in the industry, showcasing a dynamic period of innovation and regulatory evolution.Corcept Therapeutics has celebrated a significant win with their Phase 3 trial for relacorilant targeting ovarian cancer, revealing improved overall survival rates. This marks a potential rebound for Corcept following a previous FDA rejection for Cushing's syndrome, setting the stage for an impactful new cancer therapy. The success of this trial underscores the critical importance of positive clinical outcomes in securing regulatory approvals and preparing for market entry.Bristol Myers Squibb has embarked on an ambitious $850 million partnership with Janux Therapeutics to develop a novel tumor-activated therapeutic using T-cell engager technology. This collaboration is part of an ongoing trend towards personalized medicine and immunotherapy, where targeted treatments are preferred for their specificity and reduced systemic toxicity. Such partnerships not only combine resources but also accelerate the development of innovative cancer treatments.Corxel Pharmaceuticals has secured $287 million in Series D funding to advance its oral GLP-1 receptor agonist through Phase 2/3 trials addressing obesity. This significant investment highlights the growing interest in treatments for metabolic disorders, particularly as obesity remains a global health challenge with substantial unmet needs. Oral GLP-1 therapies offer promise given their potential for improved patient compliance compared to injectable forms.The regulatory landscape is also evolving. The FDA has issued draft guidance on utilizing minimal residual disease (MRD) and complete response metrics to support accelerated drug approvals for multiple myeloma treatments. This reflects an adaptive approach aimed at expediting access to life-saving therapies by leveraging advanced biomarkers and response measures. It also signifies a shift towards precision medicine, where treatment efficacy is closely monitored through molecular markers.Hoth Therapeutics has reported promising Phase 2 results addressing skin toxicities caused by EGFR inhibitors, common adverse effects in cancer treatment regimens. Despite this progress in supportive oncology care, Hoth's share price has remained stagnant, potentially due to market skepticism or the need for more data to substantiate clinical benefits.The industry continues to attract significant venture capital, as evidenced by companies like Mendra launching with $82 million to focus on innovative biotech solutions. These financial infusions are crucial for advancing early-stage research into clinical applications.On the legal front, Johnson & Johnson faces challenges with ongoing talc litigation. A court-appointed official has recommended allowing expert testimony on scientific evidence linking talc products to cancer. This could impact J&J's defense strategy and underscores the importance of robust scientific validation in legal contexts.Overall, these developments reflect an industry characterized by robust innovation, strategic collaborations, and evolving regulatory frameworks. The focus on targeted therapies, personalized medicine, and accelerated approval processes underscores a commitment to addressing complex health challenges while enhancing patient care outcomes.Shifting our attention to global trends, Samsung Biologics has achieved a financial milestone by becoming the first Korean biopharmaceutical company to exceed an annual profit of 2 trillion won ($1.4 billion). This accomplishment underscores the company's robust growth trajectory and strategic positioning in the global biopharma landscape, reflecting broader trends where increased demand for biologics and bioSupport the show

Send us a textHow individuals vary in responses to carbs, fibers, and fats.TOPICS DISCUSSED:Personalized health profiling: Snyder's lab sequences genomes and measures molecules from blood, urine, and microbiomes to detect diseases early, emphasizing data-driven discovery over assumptions.Fiber variations and effects: Responses to dietary fibers vary individually, with microbiome playing a key role.Glycemic responses to carbs: People spike differently to foods like rice, potatoes, or bread; tied to insulin resistance subtypes in muscles, liver, or pancreas.Type 2 diabetes heterogeneity: 90% of diabetes cases are type 2 with subtypes like muscle or hepatic resistance; triggers include genetics and infections, with prediabetes often undetected.Continuous glucose monitors (CGMs): Affordable tools measure glucose every five minutes, revealing personal food triggers; spikes link to risks like cardiovascular disease and cancer.Lipidomics: Lipids are diverse, serving as energy sources, structural components, and signaling molecules; understudied but key in metabolism and gene expression.Maternal health & pregnancy: Metabolomics shows thousands of changes, including hormone shifts; cord blood analysis reveals fetal nutrient use and drug transfers, with markers for preterm birth or healthy outcomes.Future research: Exploring epigenetic changes in diabetes, personalized nutrition mitigation, and digital markers from wearables for mental health tied to diet and gut-brain axis.ABOUT THE GUEST: Michael Snyder, PhD is the Stanford W. Ascherman Professor of Genetics and former chair of the Department of Genetics at Stanford University School of Medicine, where he directs the Center for Genomics and Personalized Medicine.Support the showHealth Products by M&M Partners: SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code TRIKOMES for 20% off. Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Understanding and Treating Complex Illnesses with Dr. Neil Nathan, author of “Toxic 2nd Edition: Heal Your Body from Mold Toxicity, Lyme Disease, Multiple Chemical Sensitivities, and Chronic Environmental Illness.” Dr. Nathan shares his expertise on the multifaceted nature of chronic illnesses, which often defy simple categorization and may be misdiagnosed as psychiatric issues. The discussion covers the impact of environmental toxins, electromagnetic fields, and infections like Lyme disease and long COVID. Dr. Nathan also highlights the importance of understanding inflammation's complex pathways and offers suggestions for both elimination of root causes and restoration of immune system functionality. The episode provides insights into new diagnostic tools and treatment methodologies for persistent and intrusive health issues.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we delve into the year 2025, it's clear that the pharmaceutical and biotech industries have been navigating a complex landscape filled with both challenges and remarkable advancements. Despite regulatory uncertainties and broader economic fluctuations, the FDA approved 55 new treatments and vaccines this year. Although this figure represents a slight decline from previous years, it underscores the sector's resilience and steadfast commitment to innovation even amid external pressures.One significant development in oncology comes from Incyte, which is advancing its application for FDA approval of a seven-drug Monjuvi regimen as a first-line treatment for diffuse large B-cell lymphoma. This move is backed by positive Phase 3 trial results, highlighting Monjuvi's potential to enhance treatment options for this aggressive cancer type. However, Incyte may face hurdles in gaining regulatory approval and achieving commercial success, reflecting the competitive nature of oncology therapeutics.In obesity management, Novo Nordisk introduced its once-daily Wegovy pill in the U.S., marking a milestone in the field. Priced at $149 per month for cash-paying patients with potential discounts for those insured, Wegovy's launch could shift market dynamics significantly by offering a more accessible treatment option. This aligns with the growing global focus on obesity as a critical public health issue.The industry also saw substantial investments to bolster manufacturing capabilities. Daiichi Sankyo announced plans to invest $1.9 billion to expand Enhertu production facilities across countries such as the United States, China, Japan, and Germany. This strategic move aims to strengthen supply chain robustness and meet anticipated demand for Enhertu, a pivotal player in cancer therapeutics. Meanwhile, economic pressures are palpable as drugmakers raised prices on over 350 products at the start of the year, surpassing previous years' increases. This reflects ongoing tensions around drug pricing policies and affordability, posing challenges for industry stakeholders and patients alike.The labor landscape within biopharma has been affected as well, with layoffs increasing by 16% year-over-year in 2025. These reductions highlight ongoing cost-cutting measures amid financial uncertainties and strategic realignments within companies. Yet, strategic partnerships continue to shape research and development efforts, particularly in autoimmune diseases. Sanofi's collaboration with AI biotech Earendil Labs could potentially reach $2.5 billion, emphasizing the increasing role of artificial intelligence in drug discovery and development processes. These collaborations are poised to accelerate advancements in personalized medicine and innovative therapeutic approaches.Regulatory activities have also seen notable developments this year. GSK's Nucala received approval for treating COPD in China, expanding its therapeutic scope beyond asthma. This regulatory progress signifies opportunities for existing drugs to access new markets and indications. However, the National Institutes of Health faced leadership challenges with the departure of its National Institute of Neurological Disorders and Stroke director. This adds to a series of leadership changes across NIH institutes, raising concerns about stability within this pivotal organization responsible for advancing medical research.Turning now to significant scientific advancements and clinical trials, promising results emerged from studies focused on cellular energy boosters aimed at treating Alzheimer's disease. A molecule that restores cellular energy was shown to reverse cognitive decline in mice with advanced Alzheimer's, suggesting a potential new class of therapeutics for this debilitating condition. Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into some of the latest breakthroughs and shifts shaping the industry landscape.In recent weeks, the pharmaceutical world has been abuzz with news of a groundbreaking new therapy that offers hope for patients with a rare genetic disorder. This novel treatment utilizes cutting-edge gene-editing technology, specifically CRISPR-Cas9, to target and correct genetic mutations at their source. By precisely editing the DNA within patient cells, this therapy promises not only to alleviate symptoms but potentially cure the disorder altogether. The implications of this development are profound, as it opens new avenues for treating a host of other genetic diseases that have long been considered incurable. Researchers are optimistic that this could herald a new era in personalized medicine.Meanwhile, on the regulatory front, significant progress has been made with the approval of a new cancer drug by the FDA. This drug, which has shown remarkable efficacy in clinical trials, targets a specific protein that is overexpressed in certain types of tumors. By inhibiting this protein, the drug effectively halts tumor growth and reduces metastasis. Such targeted therapies represent a shift towards more precise cancer treatments, minimizing damage to healthy cells and reducing side effects for patients. The FDA's decision underscores the importance of innovative approaches in oncology and sets a precedent for future approvals.In another exciting development, a recent phase III clinical trial has yielded promising results for a new Alzheimer's treatment. This monoclonal antibody targets amyloid-beta plaques in the brain, which are believed to be a key factor in the progression of Alzheimer's disease. The trial showed significant slowing of cognitive decline in patients who received the treatment compared to those on placebo. While there is still much to learn about the pathogenesis of Alzheimer's, these findings offer renewed hope for patients and their families and highlight the potential for antibody-based therapies in neurodegenerative diseases.Turning our attention to industry trends, there's a growing emphasis on sustainability within pharmaceutical manufacturing processes. Many companies are now investing in green chemistry, which focuses on designing products and processes that minimize environmental impact and reduce waste. This shift is not only driven by regulatory pressures but also by increasing consumer demand for eco-friendly products. By adopting sustainable practices, pharmaceutical companies are working to ensure that their contributions to global health do not come at the expense of planetary health.Finally, let's explore an intriguing trend within biotech: the rise of artificial intelligence (AI) and machine learning in drug discovery. These technologies are being harnessed to analyze vast datasets more efficiently than ever before, enabling researchers to identify potential drug candidates with greater speed and accuracy. AI-driven platforms can model complex biological interactions, predict molecular behavior, and even design novel compounds. As this field continues to evolve, it promises to revolutionize how new drugs are discovered and developed, potentially reducing time-to-market and bringing therapies to patients faster.These stories illustrate just how dynamic and innovative the pharmaceutical and biotech industries continue to be. With every breakthrough and development, there comes new hope for tackling some of humanity's most challenging health issues. Thank you for joining us today on Pharma Daily as we continue to explore these exciting advancements in science and medicine.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show

Show notes: (0:00) Intro (0:41) Who is Dr. Michael Snyder, and what does he do? (3:44) Catching type 2 diabetes early through personal health tracking (5:59) Why knowing your health baseline matters more than one-time scans (8:49) Using smartwatches to detect illness before symptoms (12:02) Tracking health on a budget (17:04) Why glucose monitors may be the most powerful health tool (18:26) Diabetes subtypes and why one diet does not work for everyone (20:57) Figuring out your diabetic type (24:57) Diet and foods for diabetes (31:55) GLP-1 drugs, benefits, risks, and who they help most (40:26) Genetics vs. epigenetics (44:41) Current studies (46:00) DNA sequence and DNA methylation (48:27) Outro   Who is Dr. Michael Snyder?  Michael Snyder, PhD, is a professor at Stanford University School of Medicine, former chair of Genetics, and director of the Stanford Center for Genomics and Personalized Medicine. He is a leader in genomics and personalized health, known for using DNA, blood data, imaging, and wearable devices to track health early and prevent disease. His research focuses on studying people while they are healthy to catch problems before symptoms appear. Dr. Snyder has published hundreds of scientific papers, launched multiple health tech companies, and authored Genomics and Personalized Medicine: What Everyone Needs to Know. His goal is to shift medicine from sick care to true health care.   Connect with Dr. Snyder Website: https://med.stanford.edu/content/sm/snyderlab.html/ Links and Resources: Peak Performance Life - https://buypeakperformance.com/ Peak Performance on Facebook - https://www.facebook.com/livepeakperformance/ Peak Performance on Instagram - https://www.instagram.com/livepeakperformance

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show

In this episode, our guest is Kate Campbell, PharmD, who serves as the Director of Pharmacy at Olympia Pharmacy. She is a proud alumna of the University of Florida, graduating Cum Laude with a bachelor's degree in biology and a doctorate in pharmacy. Dr. Campbell's previous work experiences in retail and hospital pharmacy have led to a passion for whole-person care and preventive medicine, prompting her shift towards compounding. In her pursuit, she has become a certified hormone replacement therapy specialist with a focus on bioidentical hormone replacement therapy for females.In her personal time, Kate loves connecting with her family and friends. She especially enjoys getting out on the water, playing pickleball and trying new restaurants.1. Opening & BackgroundKate, welcome to the show! Can you start by sharing your journey into pharmacy and what ultimately drew you toward compounding and personalized medicine?You've worked in both retail and hospital settings before moving into compounding—what gaps did you notice in traditional pharmacy that compounding helps to fill?How did your education at the University of Florida shape your path and perspective on whole-person care?2. Understanding Compounding & Regulatory LandscapeFor listeners who may not be familiar, can you explain the difference between 503A and 503B compounding pharmacies?What are some of the key compliance and quality distinctions between these two types of operations?Olympia Pharmacy operates under a 503B designation—what advantages does that provide in terms of scalability, safety, and product consistency?How do you see the role of compounding evolving as more patients seek individualized therapies?3. Hormone Replacement & Preventive MedicineYou're a certified hormone replacement therapy specialist, focusing on bioidentical hormones for women. What drew you to that niche?What are some of the biggest misconceptions about bioidentical hormone therapy?How do you personalize treatment for women across different stages of life—perimenopause, menopause, and beyond?What are the key questions women should ask their providers when considering hormone replacement therapy?4. Longevity & Wellness TrendsLongevity is becoming a buzzword in healthcare. From your vantage point, what longevity-focused products or therapies are worth the hype—and which are not?What innovations are you most excited about in the patient wellness space for the upcoming year?How is Olympia Pharmacy staying ahead of emerging trends—whether it's peptides, nootropics, or nutraceuticals?5. GLP-1s and Post-Therapy CareGLP-1 medications like semaglutide and tirzepatide have transformed weight management—but we're seeing challenges after patients discontinue them.What strategies or compounded therapies are helping patients maintain results post-GLP-1 use?How can pharmacists play a role in supporting metabolic health and sustainability beyond the initial weight-loss phase?6. Leadership, Lifestyle & Personal BalanceAs a director and pharmacist, how do you balance the science of pharmacy with the art of patient care?You've mentioned enjoying pickleball, the water, and exploring new restaurants—how do you recharge outside of work?What advice would you give to other pharmacists looking to explore nontraditional or entrepreneurial paths in pharmacy?7. ClosingWhat's next for you and Olympia Pharmacy?How can listeners connect with you or learn more about the services Olympia offers? ★ Support this podcast on Patreon ★

In this Deep Dive episode of The Trip Lab, we unpack hyperlipidemia (high cholesterol) beyond the oversimplified “LDL bad, HDL good” narrative. We also take a clear-eyed look at the most common concerns people have about statins, what the evidence actually shows, and where these medications fit—and don't fit—within a thoughtful, individualized approach to cardiovascular risk.From there, we explore integrative strategies for managing elevated cholesterol and why, for many patients, lifestyle, metabolic health, and inflammation-targeted interventions may be more effective than medications alone.In this episode, we discuss:Why cholesterol is biologically essential and not inherently pathologicalThe limitations of relying on LDL alone to assess cardiovascular riskHow inflammation, insulin resistance, genetics, hormones, and lifestyle influence lipid metabolismWhen elevated cholesterol truly signals disease—and when it may reflect a compensatory or adaptive responseThe role of advanced markers such as ApoB, Lp(a), hsCRP and CAC scoresWhy risk stratification—not fear-based medicine—should guide clinical decision-makingWhat statins can (and cannot do) and we break down the concerns people have with themWhy integrative approaches (nutrition, exercise, herbal options and mind-body medicine) truly treat the root cause of diseaseThis episode is for clinicians, patients, and anyone looking to move beyond simplistic cholesterol narratives toward a more nuanced, evidence-based understanding of cardiovascular health.

Pharma Influence & Why Patient Voices Matter Lobbying Power: Eli Lilly, Novo Nordisk, and Government Access Why GLP-1 Medication Access Is at Risk Introducing Sabina Hemi & the Mission of GLP Winner Why Compounded GLP-1s Matter for Real Patients The Federal “Safe Drugs” Bill: What It Claims vs What It Does Why This Bill Raises Red Flags for Patients What Real Compounding Safety Reform Would Look Like How Compounding Pharmacies Are Actually Regulated Today Prescription Reporting vs Patient Safety Is This Bill About Safety or Litigation Data? Dose Flexibility, Personalized Medicine, and Compounding Florida SB 860: A Direct Threat to Compounded GLP-1s Why Florida Compounding Impacts the Entire Country Why Obesity Medications Are Being Singled Out Active Pharmaceutical Ingredients (API): What Patients Should Know FDA Oversight, the “Green List,” and State Overreach Why Florida's API & COA Requirements Don't Add Up FDA Inspection Backlogs & Impossible Compliance Standards Branded Drug Safety Issues vs Compounding Scrutiny Catalent, Novo Nordisk, and Manufacturing Concerns Counterfeit Ozempic: The Overlooked Safety Crisis Why Supply Chain Integrity Should Be the Priority What Patients Can Do Right Now Petitions, Advocacy, and Making Your Voice Heard Florida Residents: Why Local Action Matters Final Thoughts on Access, Power, and Patient Advocacy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

https://funmedinstitute.com

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Kashif Khan discuss the intersection of genetics, health, and longevity. Kashif shares his personal journey from illness to founding the DNA company, emphasizing the importance of personalized medicine and genetic testing. They explore the unique health challenges faced by women, the impact of trauma and stress on health, and the need for individualized approaches in biohacking. The conversation highlights the significance of understanding hormone metabolism and the role of genetics in parenting, ultimately advocating for a comprehensive analysis of health to achieve optimal outcomes.   For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways ·        Genetics play a crucial role in understanding individual health. ·        Personalized medicine is essential for effective treatment. ·        Women face unique health challenges that are often overlooked. ·        Understanding hormone metabolism is key to preventing health issues. ·        Trauma and stress can significantly impact health outcomes. ·        Biohacking should be individualized, not one-size-fits-all. ·        Nervous system regulation is vital for overall health. ·        Genetic predispositions can reveal superpowers and vulnerabilities. ·        Parenting can be enhanced through understanding children's genetics. ·        Comprehensive analysis is necessary for accurate health assessments.     Chapters 00:00 Introduction to Kashif and His Journey 05:37 The Role of Genetics in Health 08:12 Understanding Individual Health Through Multiple Lenses 11:12 The Importance of Personalized Medicine 14:00 The Intersection of Genetics and Trauma 17:04 Navigating the Biohacking Landscape 19:54 The Impact of Stress and Anxiety on Health 22:59 Transforming Trauma into Superpowers 29:04 The Impact of Social Media on Identity 30:01 Understanding Genetic Potential in Children 32:32 Personalized Parenting Through Genetic Insights 38:39 Women's Health: A Neglected Area 41:25 Hormonal Health and Cancer Risks 47:32 The Precision of Hormonal Treatments   To learn more about Kashif: Email:  kash@kashkhanofficial.com Website: https://kashkhanofficial.com/   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.On the Flyover Conservatives Show, we sat down with Dr. Nick and Leah Wilson for a shocking deep dive into the rapid push for newborn DNA harvesting and the hidden dangers behind the rise of “personalized medicine.” They uncover how whole-genome sequencing, gene-therapy failures, national DNA databases, and the medical-industrial complex are converging into a system of unprecedented control over the next generation. This conversation will wake up parents, challenge long-held assumptions, and equip families to step back into the driver's seat of their health decisions.TO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comTO WATCH ALL FLYOVER CONTENT: www.theflyoverapp.comFollow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Follow and Subscribe on YouTube: https://www.youtube.com/@TheFlyoverConservativesShow Dr. Nick and Leah WilsonDr. Nick and Leah WilsonWEBSITE: www.StandForHealthFreedom.com WEBSITE: www.StandForHealthFreedom.comwww.StandForHealthFreedom.com BOOK: https://a.co/d/d9dbqTh BOOK: https://a.co/d/d9dbqThhttps://a.co/d/d9dbqTh Dr. Nick Wilson is a chiropractor, wellness expert, and leading voice in the movement to exit conventional medicine and return to principles of natural health, vitality, and personal responsSend us a message... we can't reply, but we read them all!Support the show► ReAwaken America- text the word FLYOVER to 918-851-0102 (Message and data rates may apply. Terms/privacy: 40509-info.com) ► Kirk Elliott PHD - http://FlyoverGold.com ► My Pillow - https://MyPillow.com/Flyover ► ALL LINKS: https://sociatap.com/FlyoverConservatives

Welcome to Episode 284 of Autism Parenting Secrets.If you've been listening for a while, you know I talk a lot about personalized support — not as a slogan, but because it truly changes outcomes for parents.I used to believe I had to figure everything out alone. I thought muscling through was strength.But that approach made everything heavier, slower, and far more painful than it needed to be.In this episode, I break down why going it alone holds parents back — and why expanding your vision and getting supported helps you move forward faster and with far less weight on your shoulders.The secret this week is…You DON'T Have To Carry It AllYou'll Discover:Why Lowering Your Expectations Quietly Slows Progress (1:05)The Hidden Trap Of “Lesser Goals” And How It Shows Up (2:10)How The Caddy Analogy Reveals What Parents Are Missing (3:45)The Hypocrisy Trap And Why Alignment Changes Everything (5:00)What Happened In The Twins Study And Why It Matters For Your Family (9:45)References In This Episode:Start TodayAutism Parenting Secrets: Episode 220 - Parent Coaching Is the CatalystReversal of Autism Symptoms among Dizygotic Twins through a Personalized Lifestyle and Environmental Modification Approach: A Case Report and Review of the Literature, The Journal of Personalized Medicine, Volume 14, Issue 6Additional Resources:To learn more about personalized 1:1 support, go to www.elevatehowyounavigate.comTake The Quiz: What's YOUR Top Autism Parenting Blindspot?If you enjoyed this episode, share it with your friends.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com The path to truly personalized, affordable medicine runs through data-driven operations, mature software, and disciplined execution. In this episode, Patrick Schinzel, Chief Operating Officer of Strive Pharmacy, shares his first-time HLTH insights and explores how Strive's nationwide compounding model delivers precision therapies with both speed and scale. He explains how a cash-pay pricing strategy broadens access, even as challenges remain for Medicaid and Medicare populations. From the operator's seat, Patrick highlights how analytics aligned clinical freedom with operational efficiency, out of 370 testosterone-boosting combinations, data revealed five consistently effective SKUs that improved delivery times, reduced costs, and enhanced outcomes without limiting physicians. He also details proactive potency testing on sterile lines to ensure efficacy, describes the shift from bespoke precision to “preferred” formulations for scalable personalization, and predicts that maturing software and robotics will soon make “lot size of one” production a reality. Tune in and discover how data, software, and intelligent operations are transforming personalized medicine into scalable, affordable care! Resources: Connect with and follow Patrick Schinzel on LinkedIn. Follow Strive Pharmacy on LinkedIn and visit their website! Email Patrick here.

Soup in cold weatherStudy: No benefit from beta-blockers post heart attack, but vitamin D cuts risk of 2nd heart attack in half!New study links oxalic acid to gadolinium side effects and toxicityMore on the assault on young people's brains

What can I do about a hip labrum tear?Are there any specific water filters that you recommend?What say you about lead levels in dark chocolate?

In this illuminating episode of Keeping Abreast, Dr. Jenn Simmons sits down with Dr. Taz Bhatia, board-certified physician, integrative medicine pioneer, and champion for women's health, to explore the intricate world of hormones through every season of a woman's life.Dr. Taz shares her personal hormonal journey, the gaps she witnessed in conventional medicine, and why personalized, root-cause driven care is essential. Together, she and Dr. Jenn break down how birth control, stress, gut health, and generational patterns shape hormonal balance. They also dive into innovative diagnostic approaches, including the auria test, and discuss why hormones are often misunderstood, and mismanaged, in modern medical systems.This conversation empowers women to understand their physiology, challenge outdated narratives, and take an active role in their health across puberty, fertility, perimenopause, and beyond.In This Episode, You Will Learn:Why hormonal changes form a lifelong continuumHow birth control can mask deeper imbalancesThe role of gut health and liver detoxification in hormone balanceWhy progesterone deficiency is so common todayHow stress and cortisol impact young women's hormonesThe importance of personalized hormone therapyWhy patients must advocate for their own healthHow hormonal patterns can be passed through generationsWhy breast cancer is often linked to hormone deficiency, not excessHow innovative tools like the auria test may revolutionize screeningEpisode Timeline Highlights:00:00 Introduction & Dr. Taz's personal hormonal journey 02:45 Why traditional hormonal treatments fall short 06:02 How experience reshaped her integrative practice 09:06 Birth control concerns & long-term impacts 11:57 How hormonal suppression affects whole-body health 14:58 The value of holistic, root-cause approaches 17:53 Cultural resistance to new medical paradigms 20:57 Innovations in breast cancer screening (auria test) 23:50 Why change is so hard in established medicine 27:00 Understanding hormonal patterns & testing 29:51 The need for comprehensive hormone education 33:39 Hormonal shifts from puberty to menopause 43:53 Personalized hormone therapy done right 01:01:29 Gut health, the microbiome & hormonal balance 01:04:47 Empowering patients to own their health journeyWhere to find Dr. Taz Bhatia:Website: holplus.coSocial: @DrTazMDTo talk to a member of Dr. Jenn's team and learn more about working privately with RHMD, visit: https://jennsimmons.simplero.com/page/377266?kuid=327aca17-5135-44cf-9210-c0b77a56e26d&kref=vOKy0sAiorrKTo get your copy of Dr. Jenn's book, The Smart Woman's Guide to Breast Cancer, visit: https://tinyurl.com/SmartWomansBreastCancerGuideTo purchase the auria breast cancer screening test go here https://auria.care/ and use the code DRJENN20 for 20% Off.Connect with Dr. Jenn:Website: https://www.realhealthmd.com/Facebook: https://www.facebook.com/DrJennSimmonsInstagram: https://www.instagram.com/drjennsimmons/YouTube: https://www.youtube.com/@dr.jennsimmons

About Patrick Schinzel:Patrick Schinzel is the Chief Operations Officer at Strive Pharmacy, where he has been instrumental in driving operational excellence and patient-focused innovation since 2023. With over two decades of experience in pharmacy leadership, Patrick brings a deep understanding of both clinical care and business strategy. Before stepping into his current executive role, he served as a pharmacist at Strive Pharmacy and Walgreens, where he spent nearly 20 years ensuring top-quality patient care and operational efficiency. Beyond pharmacy, Patrick has also demonstrated entrepreneurial drive as the long-time owner of Potential Home Buyers LLC, a real estate venture he has led since 2008. He earned his PharmD and bachelor's in pharmaceutical sciences from South Dakota State University, following his studies at the University of Nebraska–Lincoln and Clarke Community. Based in Mesa, Arizona, Patrick combines his expertise in healthcare and business to advance Strive Pharmacy's mission of delivering accessible, personalized, and high-quality pharmaceutical care.Things You'll Learn:Usage analytics revealed five consistently effective testosterone formulations from 370 variations, enabling faster fulfillment, lower prices, and maintained clinical autonomy.A thoughtful cash-pay strategy can enhance affordability today, even as broader reimbursement for underserved populations remains a significant industry challenge.Proactive potency testing on sterile lines (including GLP-1s) goes beyond basic safety to verify therapeutic effectiveness.“Preferred” formulations can coexist with precision medicine, extracting bulk efficiencies without eliminating personalization.The next leap is software that coordinates interdepartmental nuance, paving the way for robotics to deliver true “lot size of one” at scale.Resources:Connect with and follow Patrick Schinzel on LinkedIn.Follow Clinical Architecture on LinkedIn and visit their website. Email Patrick here.

Dr. Hoffman continues his conversation with Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance.

Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance, discusses the importance of targeted nutrients for women's health. They delve into various supplements such as magnesium, myo-inositol, progesterone cream, D-Mannose, and biotin, explaining their benefits for conditions like PCOS, blood sugar regulation, menstrual migraines, urinary tract infections, and overall skin, hair, and nail health. The conversation also touches on the importance of tailoring nutrients to individual needs and the role of personalized nutrition in supporting women's health amidst modern stresses.

In this deeply inspiring episode of Keeping Abreast, Dr. Jenn Simmons welcomes Dr. Pete Sulack—chiropractor, functional medicine practitioner, and founder of Unhealthy Anonymous—for a powerful conversation about defying the odds after a terminal cancer diagnosis.Dr. Sulack shares how he turned a death sentence into a journey of hope, healing, and renewal. Through faith, nutrition, and lifestyle transformation, he reclaimed his health and now guides others to do the same. Together, he and Dr. Jenn challenge conventional cancer paradigms, exploring how mindset, personalized nutrition, and spiritual alignment can unlock the body's innate capacity to heal.This episode invites listeners to rethink what's possible in cancer recovery and beyond. It's a story of courage, resilience, and faith in both science and spirit—reminding us that health is not something we outsource but something we build from within.In This Episode, You Will Learn:How Dr. Sulack overcame a terminal brain cancer diagnosisWhy functional medicine focuses on healing the whole person, not just treating diseaseThe crucial role of personalized nutrition in recoveryHow food sensitivities and gut health shape overall wellnessWhy conventional medicine often overlooks the importance of dietThe link between faith, mindset, and the body's innate ability to healHow to take proactive responsibility for your healthWhy empowerment and education can change the cancer care paradigm

In this episode, Dr. Jockers talks with Dr. Joel Warsh about what doctors aren't taught about vaccines in medical school and why long-term safety research is still missing. They explore how the rise in chronic illness among kids might connect to current vaccine practices. Dr. Warsh explains why asking hard questions isn't being "anti-science" — it's how we make medicine safer. He shares why vaccine schedules should be personalized and how real informed consent helps parents make better choices. Together, they break down what's actually in vaccines, how they're tested, and why open, honest conversations about health are long overdue. In This Episode: 00:00 Introduction: Vaccine Safety Concerns 02:38 Interview Introduction: Dr. Joel Warsh 02:51 The Chronic Disease Epidemic in Children 04:06 Personal Stance on Vaccination 06:33 The Rise of Chronic Diseases in Children 08:28 Factors Contributing to Chronic Diseases 09:50 Political and Environmental Influences on Health 17:30 The Role of Medications in Modern Health 19:29 Medical Training and Nutrition 23:59 Historical Context of Vaccines 30:32 How Vaccines Work and Personalized Medicine 33:59 Exploring Vaccine Reactions and Genetic Testing 36:38 The Controversy Surrounding Hepatitis B Vaccine 41:21 Questioning Vaccine Safety and Placebo Studies 45:42 Concerns About Vaccine Ingredients 59:33 The Need for Better Vaccines and Open Discussion 01:03:58 Conclusion and Final Thoughts If you want a nutrient-packed boost, check out Paleo Valley's Grass-Fed Organ Complex—a supercharged multivitamin containing liver, heart, and kidney from healthy pasture-raised cows. It delivers a full spectrum of B vitamins, minerals, amino acids, and peptides without the strong taste of organ meat. For a 15% discount, visit paleovalley.com/jockers and stock up on this powerful supplement to support energy, mental clarity, and overall health. Looking to boost your digestion, immunity, and energy? Just Thrive Probiotic is the answer! Unlike most probiotics that get destroyed by stomach acid, Just Thrive is clinically proven to reach your gut 100% alive. This means better digestion, improved immunity, enhanced energy, and easier weight management. Plus, with their industry-leading 100% money-back guarantee, you've got nothing to lose. Save 20% off your order with code JOCKERS at justthrivehealth.com. "It's not about whether vaccines are good or bad, but about creating a system that better assesses their long-term safety and impacts." Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio Resources: Get 15% off Paleovalley: paleovalley.com/jockers – Use code JOCKERS Save 20% on Just Thrive: justthrivehealth.com – Use code JOCKERS Connect with Dr. Joel Warsh: Website: https://integrativepediatrics.com/ Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https:/www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman is joined by Dr. Alexandra Shustina, a distinguished integrative gastroenterologist based in New York City and Miami. They delve into Dr. Shustina's journey from conventional to integrative medicine, the importance of addressing the microbiome, and holistic approaches to treating gastrointestinal ailments like IBS, Crohn's disease, and ulcerative colitis. Dr. Shustina shares her insights on diet, the impact of stress, and the role of supplements and herbal remedies. She discusses the significance of personalized care, visceral manipulation, and mind-body techniques in promoting gut health. The episode also touches on the rising incidence of gastrointestinal cancers in young people and the potential benefits of proactive, integrative healthcare approaches.

Dr. Hoffman continues his conversation with Dr. Alexandra Shustina, NYC's and Miami's premier Integrative board-certified Gastroenterologist and gut health specialist, an expert in the gut microbiome and its role in health and wellness.

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Millions of people are living with unexplained symptoms like allergies, brain fog, anxiety, and chronic fatigue without realizing the hidden cause: mast cells gone rogue. In this episode of The Human Upgrade, Host Dave Asprey sits down with leading functional medicine physician Dr. Tania Dempsey to uncover how Mast Cell Activation Syndrome (MCAS) drives inflammation, disrupts mitochondria, and sabotages metabolism—and what you can do to switch it off. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dr. Dempsey is internationally recognized for her work in functional medicine, biohacking, and chronic illness. She co-founded the AIM Center for Personalized Medicine, has published groundbreaking research on MCAS with Dr. Lawrence Afrin, and treats some of the most complex cases of immune dysregulation, autoimmune disease, and environmental illness. Her expertise helps you understand why mast cells are the missing link in allergies, long COVID, Lyme, mold toxicity, and even hormone disruption—and how to reclaim control of your biology. Dave and Dr. Dempsey break down how mast cells interact with mitochondria, hormones, and the nervous system, showing how chronic inflammation accelerates aging and blocks human performance. You'll discover why biohacking tools like fasting, ketosis, supplements, red light, cold therapy, sleep optimization, and smarter not harder lifestyle strategies all influence mast cell stability. They also explore why brain optimization, neuroplasticity, and nootropics are essential for calming inflammatory cascades, and how functional medicine provides practical solutions beyond conventional treatment. You'll Learn: • Why mast cells are the hidden switch behind allergies, chronic inflammation, and brain fog • How mitochondria and mast cells work together to drive human performance—or disease • The connection between toxic mold, Lyme, long COVID, hormone imbalance, and MCAS • How supplements, fasting, ketosis, and cold therapy stabilize mast cells and boost longevity • Why functional medicine and biohacking are essential for complex chronic illness • How mast cells impact metabolism, sleep optimization, and neuroplasticity • The surprising link between mast cells, anxiety, and mental health symptoms This episode is essential for anyone serious about hacking inflammation, protecting longevity, upgrading metabolism, and achieving high performance with resilience and clarity. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting-edge insights in health, performance, neuroscience, supplements, nutrition, hacking, emotional intelligence, and conscious living. Episodes are released every Tuesday, Thursday, and Friday (audio-only) where Dave asks the questions no one else dares, and brings you real tools to become more resilient, aware, and high performing. Keywords: mast cell activation syndrome, MCAS, chronic inflammation, mitochondria dysfunction, histamine intolerance, functional medicine, biohacking, allergies, brain fog, long covid, mold toxicity, Bartonella, Lyme co-infections, oxalates, salicylates, mast cell stabilizers, immune dysregulation, neuroinflammation, chronic fatigue syndrome, autoimmune triggers, personalized medicine, longevity supplements Thank you to our sponsors!Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off.LMNT | Free LMNT Sample Pack with any drink mix purchase by going to https://drinklmnt.com/DAVE.Resources: • Tania's Website: https://drtaniadempsey.com/ • Danger Coffee: https://dangercoffee.com/DAVE15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 00:00 — Trailer 01:10 — Introduction 03:27 — Why So Sick Today? 05:57 — MCAS Explained 08:33 — Mold & Environment 11:36 — Spotting MCAS 13:43 — Personal Stories 15:15 — Research & Biohacking 16:35 — Managing Triggers 20:15 — Gut & Stomach Acid 22:42 — Reaction Timing 25:30 — Hormones & MCAS 28:39 — Thyroid & Mitochondria 32:28 — Chronic Illness Navigation 40:06 — Insurance Battles 44:44 — Cholesterol & Ethics 49:11 — Personalized Care 53:24 — Circadian & Stress 58:24 — Testing Approaches 01:01:35 — Collagen & Joints 01:04:34 — MMPs & Aging 01:09:12 — Access & Experimentation 01:13:14 — MCAS & Mental Health 01:17:46 — Benzos & Stigma 01:20:23 — Vaccines & Spike Protein 01:25:18 — Research & Treatments 01:26:12 — Nicotine & Focus 01:29:24 — Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.